Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) has been given a €68.00 ($73.12) target price by equities research analysts at Barclays in a report issued on Tuesday, Borsen Zeitung reports. Barclays‘s target price indicates a potential upside of 12.58% from the company’s current price.
Other analysts also recently issued reports about the company. Credit Suisse Group set a €61.00 ($65.59) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, February 28th. Jefferies Financial Group set a €53.00 ($56.99) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, February 22nd. The Goldman Sachs Group set a €71.00 ($76.34) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, March 22nd. Deutsche Bank Aktiengesellschaft set a €58.00 ($62.37) price target on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, March 22nd. Finally, JPMorgan Chase & Co. set a €48.70 ($52.37) price target on Fresenius Medical Care AG & Co. KGaA in a research note on Monday, March 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of €65.47 ($70.40).
Shares of FME traded down €1.42 ($1.53) during trading hours on Tuesday, hitting €60.40 ($64.95). The stock had a trading volume of 605,274 shares, compared to its average volume of 704,197. The company has a debt-to-equity ratio of 95.29, a current ratio of 1.10 and a quick ratio of 0.76. The firm has a 50 day simple moving average of €59.61 and a 200-day simple moving average of €58.60. The firm has a market capitalization of $17.70 billion and a P/E ratio of 18.25. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €50.98 ($54.82) and a 1-year high of €71.14 ($76.49).
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
- The Sherwin-Williams Company Bottoms Above Institutional Support
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.